A study found that individuals with low- or intermediate-risk monoclonal gammopathy of undetermined significance, a multiple myeloma precursor, can progress to high-risk MGUS and may develop into multiple myeloma within five years, according to a study in JAMA Oncology. Based on their findings, Memorial Sloan Kettering Cancer Center researchers recommend that all patients with MGUS undergo risk assessment and blood testing.
Presence of myeloma precursor could advance disease within 5 years
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.